Durysta FDA Approval History
Last updated by Judith Stewart, BPharm on Aug 3, 2020.
FDA Approved: Yes (First approved March 3, 2020)
Brand name: Durysta
Generic name: bimatoprost
Dosage form: Implant
Company: Allergan plc
Treatment for: Glaucoma, Open Angle, Intraocular Hypertension
Durysta (bimatoprost implant) is a prostaglandin analog indicated for the reduction of intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension (OHT).
Development timeline for Durysta
| Date | Article |
|---|---|
| Mar 5, 2020 | Approval FDA Approves Durysta (bimatoprost implant) to Lower Intraocular Pressure In Open-Angle Glaucoma or Ocular Hypertension Patients |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
